Cheng Liu

Cheng Liu

Company: Eureka Therapeutics

Job title: Founder & CEO


Acknowledging the Advantages of a TCR Bispecific Antibody System 12:00 pm

• Creating effective TCR antibodies to expand the target pool • Adopting an antibody TCR technique to ease manufacturing processes • Valuing the lack of HLA restrictions with TCR antibody use to reduce off-target toxicitiesRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.